Clinical Trial Update: EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot [Phase 2]

View source ↗

Summary

Pilot Phase 2 trial update on EVOlocumab in stable heart failure with reduced ejection fraction of ischemic etiology (EVO-HF).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Fundació Institut Germans Trias i Pujol | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 2 | Status: COMPLETED